July 17, 2025

MOMA Therapeutics

MOMA Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial for MOMA-341,a Highly Potent and Selective Werner Helicase Inhibitor

July 17, 2025

Seaport Therapeutics

Seaport Therapeutics Announces First Patient Dosed in Phase 2b BUOY-1 Study of GlyphAllo (SPT-300) in Major Depressive Disorder (MDD), With or Without Anxious Distress

July 14, 2025

Marea Therapeutics

Marea Therapeutics Presents Preclinical Data on Novel Growth Hormone Receptor Antagonist Antibody, MAR002, for the Treatment of Acromegaly at ENDO 2025

July 01, 2025

Marea Therapeutics

Marea Therapeutics Appoints Shishir Gadam, Ph.D., as Chief Technical Officer

June 27, 2025

Tango Therapeutics

Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG462 plus Revolution Medicines’ Daraxonrasib or Zoldonrasib in Patients with RAS-Mutant MTAP-deleted Pancreatic or Lung Cancer

Load More

Sign up for weekly portfolio news.